Product
Revefenacin
3 clinical trials
2 indications
Indication
Chronic Obstructive Pulmonary DiseaseIndication
Acute Respiratory FailureClinical trial
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).Status: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered Via Standard Jet Nebulizer or Tiotropium Delivered Via a Dry Powder Inhaler (Spiriva® HandiHaler®)Status: Completed, Estimated PCD: 2023-11-13
Clinical trial
Revefenacin in Acute Respiratory Insufficiency in COPD (RARICO)Status: Recruiting, Estimated PCD: 2024-06-01